Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Nonsteroidal Anti-inflammatory Drugs

  • Satish K. Srivastava
  • Kota V. Ramana
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4126-2


NSAIDs are a structurally diverse group of similarly acting compounds that prevent symptoms of pain, fever, and inflammation without steroid chemistry.


NSAIDs are the most commonly prescribed drugs worldwide for the treatment of pain and inflammation. They are effective as antipyretic and analgesic and are also effective in prevention of cardiovascular complications. In recent years, evidence from animal as well as prospective and retrospective clinical studies indicate that NSAIDs may lower the risk of cancer development and more importantly progression of cancer, especially colorectal and breast cancers.

Types of NSAIDs

Depending on their strength, duration of action, and elimination from the body, NSAIDs have been classified as:
  • Salicylic acids: aspirin, salsalate, and diflunisal

  • Acetic acids: sulindac, indomethacin, diclofenac, and tolmetin

  • Propionic acids: ibuprofen, naproxen, flurbiprofen, oxaprozin, ketoprofen, and fenoprofen

  • Enolic acids: meloxicam...


Breast Cancer Bladder Cancer Adenomatous Polyp Mefenamic Acid Pleckstrin Homology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899CrossRefPubMedGoogle Scholar
  2. Bundred NJ, Barnes NL (2005) Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer 93:S10–15CrossRefPubMedPubMedCentralGoogle Scholar
  3. Dubois RN, Abramson SB, Crofford L et al (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063–1073PubMedGoogle Scholar
  4. Giardiello FM, Hamilton SR, Krush AJ et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316CrossRefPubMedGoogle Scholar
  5. Gius D, Spitz DR (2006) Redox signaling in cancer biology. Antioxid Redox Signal 8:1249–1252CrossRefPubMedGoogle Scholar
  6. Harris RE, Chlebowski RT, Jackson RD et al (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 63:6096–6101Google Scholar
  7. Lynch PM, Ayers GD, Hawk E et al (2010) The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 105:1437–1443CrossRefPubMedGoogle Scholar
  8. Pagliarulo V, Ancona P, Martines et al (2015) Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Ther Adv Urol 7:303–311CrossRefPubMedCentralGoogle Scholar
  9. Tammali R, Ramana KV, Singhal SS et al (2006) Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin e2 production in human colon cancer cells. Cancer Res 66:9705–9713CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Biochemistry and Molecular BiologyUniversity of Texas Medical BranchGalvestonUSA